AstraZeneca plc (NYSE:AZN) hit a new 52-week high on Monday . The company traded as high as $35.93 and last traded at $35.44, with a volume of 2527300 shares trading hands. The stock had previously closed at $35.07.

A number of equities research analysts recently weighed in on AZN shares. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the company a “buy” rating in a research note on Wednesday, January 10th. Citigroup upgraded shares of AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. Cowen restated a “hold” rating and issued a $37.00 target price on shares of AstraZeneca in a report on Tuesday, October 17th. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Finally, Leerink Swann restated a “market perform” rating and issued a $36.00 target price (up previously from $33.00) on shares of AstraZeneca in a report on Thursday. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $34.48.

The stock has a market cap of $88,700.00, a price-to-earnings ratio of 25.31, a price-to-earnings-growth ratio of 2.62 and a beta of 0.76. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94.

AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 earnings per share. sell-side analysts expect that AstraZeneca plc will post 1.9 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. WFG Advisors LP boosted its holdings in AstraZeneca by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after acquiring an additional 984 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in AstraZeneca in the third quarter valued at $133,000. Quadrant Capital Group LLC boosted its holdings in AstraZeneca by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after acquiring an additional 846 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new stake in AstraZeneca in the third quarter valued at $184,000. Finally, FTB Advisors Inc. boosted its holdings in AstraZeneca by 3.2% in the second quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock valued at $197,000 after acquiring an additional 200 shares in the last quarter. Institutional investors and hedge funds own 14.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: “AstraZeneca (AZN) Hits New 52-Week High at $35.93” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://theolympiareport.com/2018/01/22/astrazeneca-azn-hits-new-52-week-high-at-35-93.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.